A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF TOPICAL CLINDAMYCIN 1% GEL VERSUS TOPICAL DAPSONE 5% GEL IN ACNE VULGARIS OVER FACE: A PROSPECTIVE RANDOMIZED DOUBLE BLIND STUDY. - NIL

Start Date20 Nov 2023

Sponsor / Collaborator-

IRCT20230806059062N1 / RecruitingPhase 3IIT

Comparative evaluation of Dapsone gel 5% with Adapalene gel 0.1% in patients with acne vulgaris

Start Date23 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with Dapsone

100 Translational Medicine associated with Dapsone

100 Patents (Medical) associated with Dapsone

8,838

Literatures (Medical) associated with Dapsone

01 Jan 2025·Talanta

Natural deep eutectic solvent-based dispersive liquid-liquid microextraction of pesticides in drinking waters combined with GC-MS/MS detection

Article

Author: Hristozova, Аsya ; Canals, Antonio ; Aguirre, Miguel Ángel ; Simitchiev, Kiril ; Vidal, Lorena

The current research aims to develop a new analytical method applying a dispersive liquid-liquid microextraction (DLLME) assisted by vortex and using an environmentally friendly extractant for the preconcentration of organochlorine and organophosphorus pesticides followed by gas chromatography-tandem mass spectrometry (GC-MS/MS) analysis. The extractant (i.e., natural deep eutectic solvent (NADES)) is safe, cheap, biodegradable and can be prepared by simply mixing DL-menthol and decanoic acid (molar ratio 2:1). The main experimental factors affecting the extraction of all analytes evaluated (19 organochlorine and organophosphorus pesticides) have been optimised using a multivariate analysis consisting in two steps: a Plackett-Burman design followed by a central composite design (CCD). Seven experimental factors have been evaluated: (i) sample volume; (ii) NADES volume; (iii) sample pH; (iv) extraction time; (v) centrifugation time; (vi) centrifugation speed; and (vii) ionic strength (NaCl %, w v^-1). For the significant variables, the optimum values were 10 mL sample and 45 μL NADES. No pH adjustment as well as addition of NaCl were needed. The other variables were set at 3 min extraction time, 5 min centrifugation time and 900×g centrifugation speed, respectively. Under the optimised extraction conditions, the limit of quantification (LOQ) values ranged between 0.2 and 78 ng L^-1 for all analysed pesticides. Furthermore, the proposed analytical method has been successfully applied to drinking water (bottled spring water). The recovery study (n = 3) has been evaluated at 0.1, 1.0 and 5.0 μg L^-1 spiking levels, obtaining relative recovery values within the range of 70 % and 117 % and RSD values between 1 % and 20 % for all the analytes studied, except for p,p-DDT (56-77 % in high conductivity water samples).

31 Dec 2024·Journal of Dermatological Treatment

UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities

Article

Author: Bilo, Benedikt ; Salman, Andac ; Mann, Caroline ; Maurer, Marcus ; Bernstein, Jonathan A ; Kulthanan, Kanokvalai ; Katelaris, Connie ; Staubach, Petra ; Fluhr, Joachim W ; Krause, Karoline

BACKGROUNDThere is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities.METHODSWe present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines.RESULTSOf 212 patients, 108 (mean age 48.9 years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6 months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9 months (SD ± 3.2) and one quadruple therapy (2.1 months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria.CONCLUSIONSCombining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile.

01 Dec 2024·Environmental Pollution

Effects of the organochlorine pesticide metabolite p,p’-DDE on the gastrointestinal lipidome in fish: A novel toxicity pathway for a legacy pollutant

Article

Author: Lin, Ashley M. ; Denslow, Nancy D. ; Wormington, Alexis M ; Bisesi, Joseph H ; Bowden, John A ; Bisesi, Joseph H. ; Robinson, Sarah ; Bowden, John A. ; Gabrielli, David J ; Robinson, Sarah E ; Lin, Ashley M ; Denslow, Nancy D ; Wormington, Alexis M. ; Nouri, Mohammad-Zaman ; Gabrielli, David J. ; Sabo-Attwood, Tara

Though phased out from use in the United States, environmental contamination by organochlorine pesticides (OCPs) remains a widespread issue, especially around intensive agricultural regions. OCPs, such as dichlorodiphenyltrichloroethane (DDT) and its primary metabolite, dichlorodiphenyldichloroethylene (DDE), have been detected in soils, sediments, surface waters, and biota decades after their discontinued use. As OCPs are persistent and can bioaccumulate in fats, these compounds can transfer and magnify across food webs. Freshwater predatory fish and birds can accumulate high OCP concentrations, leading to a myriad of deleterious impacts on organismal health. Studies have found evidence of reproductive disruption in predatory fish, such as the largemouth bass (LMB; Micropterus salmoides), associated with DDT and DDE exposure. DDE can act through estrogenic pathways and induce the expression of estrogenic signals in male animals; however, the molecular mechanism of disruption is unclear. Recently, metabolomics research has revealed corollary relationships between lipid signals and organic pollutant toxicity. Here, a two-month feeding experiment on LMB was conducted to assess the interactions of DDE (as p,p'-DDE) in food with gut and liver lipid signaling. Targeted lipidomic analysis revealed global alterations in the abundance of tissue lipids, especially cholesteryl esters and phospholipids, in LMB exposed to low levels of p,p'-DDE. Results from these studies indicate that p,p'-DDE may act through disruption of normal lipid homeostasis to cause toxicity in freshwater fish.

News (Medical) associated with Dapsone

25 Oct 2024

·www.prnewswire.com

Studies Show Sun Pharma's WINLEVI® (clascoterone) Cream 1% Reduces Sebum Levels and is Suitable for Combination With Other Commonly Used Topical Acne Medications

WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference also include data affirming reduced acne severity and tolerability in patients with skin of color. MUMBAI, India and PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries or associate companies), today presented data strengthening the clinical rationale for the use of WINLEVI ® (clascoterone) cream 1% to treat acne. In poster presentations at the 44th Annual Fall Clinical Dermatology Conference, data show WINLEVI significantly reduces sebum (oil) production and demonstrates excellent stability in the presence of other commonly prescribed topical acne treatments, supporting the use of WINLEVI in combination with those medications. Data also showed patients with skin of color, an under-represented population in studies of acne medications, experienced reduced acne severity and tolerability while taking WINLEVI. Collectively, the data continue to show that WINLEVI improves acne severity and is well tolerated. "As we learn more about the importance of sebum as a main cause of acne, it is gratifying to see new data supporting the use of WINLEVI to reduce sebum production as well as its suitability for combination treatment with other commonly prescribed topical agents," said Abhay Gandhi, chief executive officer, North America at Sun Pharma. "We are also encouraged by the reported reductions in acne severity and tolerability in people with skin of color, for whom the impact of acne can be profound. Together, these latest studies further establish WINLEVI as a safe and effective acne medication that dermatology professionals can confidently prescribe to their patients." WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, and the first and only FDA-approved topical treatment available in the U.S. that targets sebum production in the skin. Sebum is an oily wax that protects and moisturizes skin, but too much of it feeds bacteria inside the skin, causing inflammation and acne lesions. Acne is the most prevalent skin condition in the U.S., affecting up to 50 million Americans and 80% of people at some point during their lives.1,2 It is the most common dermatological disorder in Black/African American and Hispanic/Latino populations.3 WINLEVI cream is a topical prescription medicine to treat acne in people 12 and older. The most common side effects include reddening, scaling or dryness, and itching. Local irritation may occur. Sebum reduction data Researchers presented 12-week interim results from a yearlong study of the effect of WINLEVI on facial sebum production in patients with acne. The study's primary objective and efficacy endpoint was reduction in casual facial sebum levels, as measured by a sebumeter, a device that directly measures the amount of lipids on the skin's surface. The study was also designed to assess the ability of WINLEVI to reduce the Investigator's Global Assessment (IGA) score, a scale designed for investigators to assess the level of facial acne (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe). Other study objectives and efficacy endpoints included inflammatory and noninflammatory acne lesion counts, and investigator-assessed oily appearance, pore size, and facial shine; the latter three endpoints were assessed on a five-point scale (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe). Among the 40 participating patients, the mean age was 20.9 years; most patients were female (60%) and White (63%). All patients entered the study with mild (57.5%) or moderate (42.5%) acne, as well as a mean sebumeter reading of 115.9 ± 50.5. The researchers reported significant reductions in sebumeter measurements following use of WINLEVI at six (-22%, P = 0.002), 10 (-19%, P = 0.005), and 12 weeks (-27%, P <0.001). They also observed significant improvements in facial oily appearance after four weeks of WINLEVI treatment (-8%, P = 0.008), with continued improvement through 12 weeks (-40%, P <0.001). Similarly, patients' pore size improved significantly after six weeks (-13%, P = 0.002), and continued to improve through 12 weeks (-23%, P <0.001). Additionally, facial shine levels significantly improved after four weeks (-9%, P = 0.004) with continued improvement through 12 weeks (-39%, P <0.001). By Week 12, patients using WINLEVI experienced a statistically significant 29% reduction in IGA score (P <0.001). Use of WINLEVI also resulted in significant reductions in the numbers of inflammatory and noninflammatory lesions (-48% and -40%, respectively; P <0.001 for both measurements) after four weeks, with continued improvement through 12 weeks (-54% and -34%, respectively; P <0.001 for both). WINLEVI was well tolerated through Week 12, with no reports of adverse reactions. "This is exciting news for people living with acne because this is the first study to demonstrate a reduction in measured facial sebum production following the use of clascoterone cream 1%," said lead investigator Zoe D. Draelos, MD, of Dermatology Consulting Services, PLLC, in High Point, N.C. "In addition to confirming the sebum-reducing effect of WINLEVI, our findings support data from previous clinical trials which showed reductions in the number of inflammatory and noninflammatory lesions, further demonstrating the clinical utility of this topical acne medication." Stability in combination therapy data Dr. Draelos and colleagues also reported results from a study assessing the stability of WINLEVI when layered with other topical acne medications such as tretinoin cream 0.025%, adapalene gel 0.3%, dapsone gel 7.5%, azelaic acid 15%, benzoyl peroxide 5%/clindamycin 1%, benzoyl peroxide 2.5%/adapalene 0.1%, and benzoyl peroxide encapsulated 5%. Each of these medications were placed separately on individual microscope slides with WINLEVI and incubated for eight hours at 37° Celsius. Material from the slides was extracted for analysis via high-performance liquid chromatography-mass spectrometry (HPLC-MS). WINLEVI concentrations remained stable after layering with other acne medications. The percentage of WINLEVI recovered after layering ranged from 98% to 119%, indicating that none of the acne medications evaluated induced degradation of WINLEVI when used in combination. "Multimodal topical therapy, incorporating products with multiple mechanisms of action to target multiple mechanisms of disease, has become standard practice in the treatment of acne," commented Dr. Draelos. "In this in vitro study, WINLEVI demonstrated consistent and reproducible stability in the presence of other acne medications. Our findings support the combination of WINLEVI with topical retinoids, topical antibiotics, and/or benzoyl peroxide as a viable acne treatment strategy and complement the encouraging results observed in the sebum reduction and skin of color trials." Skin of Color Data A separate team of researchers presented 16-week interim results from a 56-week, single-center, open-label pilot study evaluating the efficacy and safety of WINLEVI in 10 patients (mean age 24 years) with skin of color (Fitzpatrick skin types IV, V, and VI) and moderate-to-severe facial acne. The study met its primary endpoint, with seven (78%) patients achieving an IGA score of 0 (clear) or 1 (almost clear) at Week 16 (P = 0.008 vs. baseline). The study also met its secondary endpoints at Week 16, including significant reductions in inflammatory (91.8%, P = 0.008), noninflammatory (90.9%, P = 0.009), and total lesions (90.9%, P = 0.009). Investigator- and participant-assessed tolerability parameters were absent or minimal at most time points through Week 16. There were no reports of adverse events during the 16-week interim analysis period. For complete prescribing information please click here. INDICATION WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS Local Irritation: Pruritus, burning, skin redness or peeling may be experienced with WINLEVI cream. If these effects occur, discontinue or reduce the frequency of application of WINLEVI cream. Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI. In the pharmacokinetics (PK) trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14. All subjects returned to normal HPA axis function at follow-up 4 weeks after stopping treatment. Conditions which augment systemic absorption include use over large surface areas, prolonged use, and the use of occlusive dressings. Attempt to withdraw use if HPA axis suppression develops. Pediatric patients may be more susceptible to systemic toxicity. Hyperkalemia: Elevated potassium levels were observed in some subjects during the clinical trials. Shifts from normal to elevated potassium levels were observed in 5% of WINLEVI-treated subjects and 4% of vehicle-treated subjects. ADVERSE REACTIONS Most common adverse reactions occurring in 7 to 12% of patients are erythema/reddening, pruritus and scaling/dryness. Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle. About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this "document" describing Sun Pharma's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Sun Pharma does not undertake any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. References 1 Skin conditions by the numbers. American Academy of Dermatology Association, 2021. Available at Skin conditions by the numbers (aad.org). Accessed January 11, 2023. 2 Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56-59. 3 Taylor SC. Epidemiology of skin diseases in people of color. Cutis. 2003;71(4):271-275. SOURCE Sun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDrug Approval

27 Jun 2024

·www.sciencedaily.com

Novel peptide formulation shows promise of treating cognitive decline in schizophrenia

Schizophrenia is a serious mental health disorder linked to the imbalance of chemical neurotransmitters that affect cognitive capabilities. Current therapies against schizophrenia have numerous limitations, largely due to the selective permeability of blood-brain barrier, which necessitates the development of novel strategies. Schizophrenia is a complicated mental health disorder accompanied by wide range of symptoms such as hallucinations, impaired cognitive ability, and disorganized speech or behavior. It has been associated with anomalies in neurotransmission due to the imbalance of chemical neurotransmitters. Current treatment strategies against schizophrenia involve the administration of antipsychotic drugs, which can cause adverse effects and are associated with a high risk of cardiovascular disease. Moreover, in patients, response to therapeutic drugs is often inadequate as the blood-brain barrier (BBB), a protective barrier of cells, strictly regulates the movement of ions and molecules into the brain. To overcome the hurdle of BBB and facilitate the transport of therapeutic drugs into brain tissue to treat schizophrenia, researchers have explored the applicability of receptor-mediated transcytosis (RMT) using low-density lipoprotein receptor-related protein 1 (LRP1). This research was conducted by team led by Associate Professor Eijiro Miyako from Japan Advanced Institute of Science and Technology (JAIST), included Prof. Yukio Ago from Hiroshima University, Prof. Shinsaku Nakagawa from Osaka University, Prof. Takatsugu Hirokawa from Tsukuba University, and Dr. Kotaro Sakamoto, Senior Principal Scientist at Ichimaru Pharcos Co., Ltd. Their study was published in JACS Au journal on June 20, 2024. The researchers were inspired by previous findings which showed the interactions of vasoactive intestinal peptide receptor 2 (VIPR2) gene duplication in schizophrenia and their own discovery of a novel peptide, KS-133. The novel peptide, KS-133, has selective antagonist activity to VIPR2, leading to its downregulation. However, the major limitation associated with KS-133 was its poor permeability across BBB. To facilitate the effective transport of KS-133 into the brain, they developed a brain-targeting peptide, KS-487, that could specifically bind to LRP1 and influence RMT. Finally, the researchers developed a novel nanoparticle-based drug delivery system (DDS) where KS-133 peptide was encapsulated with KS-487 targeting peptide and studied its efficacy in treating schizophrenia. The administration of peptide formulations via the DDS resulted in the effective distribution of the drug in the brains of mice. Drug release profiles assessed by pharmacokinetic analysis confirmed the role of the brain-targeting peptide in transporting KS-133 into the brain. Furthermore, the efficacy of DDS was evaluated in mice with induced schizophrenia by elevated activation of VIPR2. Mice treated with KS-133/KS-487 nanoparticles showed significant improvement in cognitive functions during novel object recognition tests, which could be attributed to the inhibition of VIPR2. Explaining the real-life applications and potential of their study, Dr. Miyako shares, "Existing drugs only have mechanisms involving neurotransmitter modulation, and their therapeutic effects are limited, especially for cognitive dysfunction. Thus, our peptide formulation could be used as a novel drug to restore cognitive dysfunction in schizophrenia." In summary, this study by Dr. Miyako and co-researchers provides preclinical evidence of a novel therapeutic strategy for targeting VIPR2 that could improve cognitive impairment in schizophrenia. "Going ahead, we will extend our study to involve cells and animal models, as well as human clinical trials, to confirm the efficacy and safety of this peptide formulation and promote its development as a new treatment for schizophrenia within 5 years," concludes Dr. Miyako, optimistic about the long-term implications of their study.

21 Nov 2023

·www.globenewswire.com

Combination Antibiotic Therapies May Be Capable of Eradicating Lyme Disease, According to Investigational Study Funded by Bay Area Lyme Foundation

Study identifies persistent Lyme bacteria in tissue samples and points to need for clinical studies of combination antibiotics in persistent LymePORTOLA VALLEY, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading public foundation sponsor of Lyme disease research in the US, today announced results of a laboratory study published in the peer-reviewed journal Frontiers in Microbiology that identifies seven combination therapies that are superior to courses of single antibiotics for treating persistent Lyme disease in an investigational model. These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D., along with other researchers from Tulane University. “Our results support the experience of Lyme disease patients whose symptoms have not resolved after a standard course of antibiotics, and these new data suggest that combination therapy should be investigated in clinical studies for treating persistent human Lyme disease,” said Embers, an associate professor of microbiology and immunology and director of Vector-borne Disease Research at Tulane National Primate Research Center. While none of the single courses of antibiotics eliminated persistent infection in this investigational study, some combinations of already FDA-approved antimicrobial treatments were able to eradicate the bacteria. Specifically, four different dual combinations of antibiotics (doxycycline and ceftriaxone; dapsone and rifampicin; dapsone and clofazimine; doxycycline and cefotaxime) and three triple combinations of antibiotics and antimicrobials (doxycycline, ceftriaxone and carbomycin; doxycycline, cefotaxime and loratadine; dapsone, rifampicin and clofazimine) eradicated persistent infections of Borrelia burgdorferi, the bacteria that causes Lyme disease. “With no FDA-approved treatment for persistent Lyme, these data will bring much-needed hope to the approximately 2 million Americans who live with symptoms such as chronic pain, fatigue, and cognitive dysfunction due to this terrible disease,” said Linda Giampa, executive director of the Bay Area Lyme Foundation. “Importantly, this is yet another study demonstrating the existence of persistent infection following a standard course of antibiotics.” In this study, Borrelia burgdorferi was found in tissue cultures taken after a 28-day course of a single antibiotic treatment, supporting previous data showing that the bacteria can persist following standard treatment. Conversely, viable Borrelia burgdorferi was not detected in cultured tissues following administration of the seven treatment combinations. Previous studies funded by Bay Area Lyme Foundation also found other compounds, including natural botanicals, to show promise in killing Borrelia burgdorferi and superiority over commonly prescribed antibiotics in laboratory research. This study was made possible by Bay Area Lyme Foundation’s science research grant program, which includes support from Project Lyme. About Lyme disease The most common vector-borne infectious disease in the US, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets, and can be potentially passed from a pregnant mother to her unborn baby. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and inaccurate diagnostic tests. There are almost 500,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, up to two million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates. About Bay Area Lyme Foundation Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public not-for-profit sponsor of innovative Lyme disease research in the US. A 501c3 organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM FUND covers overhead costs and allows for 100% of all donor contributions to the Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439. Media contact: Tara DiMilia Phone: 908-369-7168 Tara.DiMilia@tmstrat.com

Qualified Infectious Disease ProductClinical Result

100 Deals associated with Dapsone

External Link

KEGG	Wiki	ATC	Drug Bank
D00592	Dapsone	J04BA02 D10AX05	DB00250

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acne Vulgaris	US	AbbVie, Inc.	07 Jul 2005
Herpesviridae Infections	-	-	31 Dec 1942
Leprosy	-	-	31 Dec 1942
Pneumonia	-	-	31 Dec 1942

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 1	US	Pulmonem, Inc.	22 Nov 2021
COVID-19	Phase 1	CA	Pulmonem, Inc.	22 Nov 2021
Acute Ischemic Stroke	Phase 1	MX	Cidat Sa De Cv	01 Jul 2009
Stroke	Phase 1	MX	Cidat Sa De Cv	01 Jul 2009
Rosacea	Phase 1	US	Allergan Ltd. (Ireland)	01 Nov 2005
Acne Vulgaris	Phase 1	-	Allergan Ltd. (Ireland)	01 Feb 2005
HIV Infections	Phase 1	PR	Jacobus Pharmaceutical Co., Inc.	31 Aug 2001
Exanthema	Preclinical	US	Allergan Ltd. (Ireland)	01 Jun 2006
Non-Small Cell Lung Cancer	Preclinical	US	Allergan Ltd. (Ireland)	01 Jun 2006
Pemphigus	Preclinical	US	Jacobus Pharmaceutical Co., Inc.	01 Nov 1996

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UK adult ITP registry (EHA2024)	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	-	Dapsone	lcorqlsbsu(fqvvqkapld) = No PLT transfusions needed during dapsone treatment lpemzcrhon (pikitwglaf ) View more	Positive	14 May 2024
DAPS-ITP (ASH2023)	Not Applicable	Purpura, Thrombocytopenic, Idiopathic Second line	93	Dapsone + Prednisone	(pxmbhbutsf) = bcjoxrrjhf cznmgrhlic (sxqllsqflf, 2.78 - 18.93)	-	11 Dec 2023
DAPS-ITP (ASH2023)	Not Applicable	Purpura, Thrombocytopenic, Idiopathic Second line	93	Prednisone	(pxmbhbutsf) = clefrofvgg cznmgrhlic (sxqllsqflf, 0.78 - 12.81)	-	11 Dec 2023
EADV2023	Not Applicable	G-6-PD levels	45	Dapsone	itcrfjavjl(kdarbyfair) = Methaemoglobinaemia was detected in 2 patients ( 4.4% ) . Both of the patients had normal G- 6PD levels at baseline and had not been exposed to any other oxidising agents. Both of them reported lowered exercise tolerance after starting dapsone, had pulse oximetry readings of 89% -92%, and methaemoglobin levels of 6.2% and 7% in arterial blood gas analysis. They did not have cyanosis, significant hemolysis or dyspnoea at rest. In both patients, symptoms resolved with cessation of dapsone. btiifqgaqu (ntsvhoetai )	Positive	11 Oct 2023
WCD2023	Not Applicable	Leprosy	36	Dapsone	iktwdsrulu(ncynfqteqt) = 25% of patients were labelled as confirmed cases of dapsone induced haemolytic anaemia as per our definition fkculqxfmk (mqqmcmjlru )	-	03 Jul 2023
EADV2023	Not Applicable	-	-	Dapsone	(effesahlut) = irmfuhtofp ugguqlbdzn (ecytssiixn )	-	18 May 2023
ASN2022	Not Applicable	Nephrosis, Lipoid glucose-6-phosphate dehydrogenase deficiency	-	Dapsone	kqboedmgbh(ynzybtwhgw) = meobftwnkq pqtcohtzms (glljplstjr )	-	03 Nov 2022
NCT03681470 (CTgov)	Phase 4	Acne Vulgaris	20	Aczone Gel	liljjdrlbp(djhvyjzene) = lomhndupon vwhxxwxoza (kpbpasmhai, gtrpjpvwpe - zduwqmrhae) View more	-	27 Jul 2022
EADV2022	Not Applicable	Moderate to severe acne	47	Dapsone 7.5% gel	iitvgwomre(poztccytvi) = nhskejmleu mdpkjkowek (oyksdgugah ) View more	Positive	12 May 2022
EADV2022	Not Applicable	Moderate to severe acne	47	Adapalene 0.1% gel	iitvgwomre(poztccytvi) = fhjgqwxhgy mdpkjkowek (oyksdgugah ) View more	Positive	12 May 2022
ASN2021	Not Applicable	Nephrosis, Lipoid	-	Dapsone	(erpsdtaxjt) = The patient had new anemia (hemoglobin was 11.3 from a baseline of 14 g/dL). She did not have signs of hemolytic anemia (LDH, bilirubin, haptoglobin and peripheral smear were normal). Her methemoglobin levels were then tested given recent initiation of dapsone and were found to be elevated at 11.5%. pmwpwsqmfd (naxqfnkmzg )	Negative	27 Oct 2021
NCT02959970 (Pubmed) Manual	Phase 4	Acne Vulgaris	-	Dapsone	(hfnkwzexyr) = low rate，and dermal tolerability scores indicated no or mild stinging/burning, dryness, scaling, and erythema txhfwjiixd (bnigydtsag ) View more	Positive	01 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis